Reports
Reports
Sale
The global acute respiratory syndrome treatment market size attained a value of USD 947.08 million in 2023, driven by the mutating variants of COVID-19 and other emerging respiratory syndromes. The market is estimated to grow at a CAGR of 10.1% during the forecast period of 2024-2032. With this growth rate, the market value is estimated to reach a value of USD 2251.50 million by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The small, elastic air sacs (alveoli) in the lungs experience fluid buildup, which results in acute respiratory distress syndrome (ARDS). Less oxygen enters circulation because of the fluid's ability to prevent the lungs from filling with enough air. The organs are deprived of the oxygen they require to function as a result.
People who are already critically ill or have severe injuries are more likely to develop ARDS. The primary symptom of ARDS, severe shortness of breath, typically appear a few hours to a few days after the injury or illness that caused it. Age and sickness severity both raise the probability of death. Among those who survive ARDS, some make a full recovery while others have lung damage that lasts for a lifetime.
The severity of ARDS's signs and symptoms might vary depending on the condition's origin, its severity, and whether the underlying heart or lung illness is present or not. They consist of severe breathlessness, breathing that is laboured and unusually quick, reduced blood pressure, dizziness, and excessive fatigue
The smallest blood arteries in the lungs leak fluid into the tiniest air sacs where the blood is oxygenated, which is the mechanical cause of ARDS. This fluid is typically kept in the vessels by a protective barrier. However, severe disease or injury can harm the membrane, resulting in fluid leakage and ARDS.
Sepsis: It is a dangerous and widespread bloodstream infection and is the most typical cause of ARDS.
Inhalation: Breathing in dangerous toxins. ARDS may develop as a result of breathing toxic gases, excessive smoke concentrationkis, aspirating vomit, or near-drowning incidents.
Pneumonia: All five lobes of the lungs are typically affected by severe pneumonia.
Injury: Chest, head, or any serious damage. Accidents that cause direct damage to the lungs or the area of the brain that regulates respiration include slips, trips, and falls.
Others like burns, major blood transfusions, and pancreatitis (pancreatic inflammation).
Majority of people who develop ARDS are already ill or injured. While it is unclear who will develop ARDS, several factors, like advanced age, history of tobacco and alcohol consumption, presence of chronic lung disease, or high-risk surgery could lead to higher vulnerability.
To assist in the diagnosis of ARDS, several diagnostic tests are employed. These tests identify the infection's source, evaluate the state of the lungs, and rule out other illnesses that present with comparable symptoms. Imaging, blood testing, and analysis of sputum (the mixture of saliva and mucus that is coughed up) are procedures that can be used to diagnose acute respiratory distress syndrome.
The percentage of patients with ARDS who are admitted to intensive care units is between 10 and 15 percent . Geographically, ARDS incidence varies and may be greater in the United States and Europe than in other regions. According to the acute respiratory syndrome market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Breakup by Drug Class:
Breakup by Route of Administration:
Based on the Treatment Channel:
Market Breakup by Region:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
No medication has been proven to be successful in preventing or treating ARDS. The goal of treatment is to keep the patient comfortable as the lungs heal. The objective of supportive care is to treat the injury that led to the development of ARDS and get enough oxygen into the blood and distributed to your body to stop damage.
Ventilator Support: Extra oxygen is required for all ARDS patients. Typically, oxygen alone is insufficient and excessive oxygen can harm the lungs. A ventilator is a device that facilitates breathing by helping to reopen closed airways. Through a face mask or a tube put into the windpipe, the patient is connected to the ventilator.
Prone Positioning: Patients with ARDS usually lie on their backs in bed. ARDS patients may occasionally be flipped over onto their stomachs to increase blood oxygen levels when oxygen and ventilator therapies are being used at high levels, but blood oxygen levels are still low. Proning is a technique that can temporarily raise blood oxygen levels. It is a challenging task, and some patients are too ill to benefit from this therapy.
Fluid Management: Patients with ARDS are given diuretics to make the patients urinate more frequently in an effort to flush the body of extra fluid and prevent it from accumulating in the lungs. Care must be taken since excessive fluid loss might reduce blood pressure and cause renal issues.
Extracorporeal Membrane Oxygenation (ECMO): In ECMO, blood is removed from the body and pumped across a membrane that adds oxygen and removes carbon dioxide before returning the blood to the body. This therapy carries a high risk and several potential drawbacks. It is not appropriate for all ARDS patients.
Due to the diverse aetiology and pathophysiology of ARDS, personalised therapy is intrinsically difficult. But repurposing medications that have been investigated in untargeted/unenriched populations could be just as inventive and promising for ARDS research as novel experimental therapeutics, including for COVID-19 ARDS. Timing, clinical phenotypes, and biologic phenotypes are some potential therapeutic targets.
Multiple medicines can also be promptly and flexibly investigated with adaptive clinical trial design. It is also possible to individually tailor supportive measures, such as ventilator management and hydration strategy. Novel therapeutics are also in the works, in addition to possible repurposing/targeting of current medications and supportive care techniques.
The report gives an in-depth analysis of the key players involved in the acute respiratory syndrome treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Drug Class |
|
Breakup by Route of Administration |
|
Breakup by Treatment Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Global Acute Respiratory Syndrome Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Acute Respiratory Syndrome Treatment Market
8.1 Global Acute Respiratory Syndrome Treatment Market Overview
8.2 Global Acute Respiratory Syndrome Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Acute Respiratory Syndrome Treatment Market Historical Value (2017-2023)
8.2.1.2 Global Acute Respiratory Syndrome Treatment Market Forecast Value (2024-2032)
8.3 Global Acute Respiratory Syndrome Treatment Market by Drug Class
8.3.1 Market Overview
8.3.1.1 Vasoconstrictor
8.3.1.2 Bronchodilators
8.3.1.3 Steroids
8.3.1.4 Antibiotics
8.3.1.5 Nitric Oxide
8.3.1.6 Sedatives and Paralytics
8.3.1.7 Surfactant
8.3.1.8 Others
8.4 Global Acute Respiratory Syndrome Treatment Market by Route of Administration
8.4.1 Market Overview
8.4.1.1 Oral
8.4.1.2 Inhalation
8.4.1.3 Parenteral
8.4.1.4 Others
8.5 Global Acute Respiratory Syndrome Treatment Market by Treatment Channel
8.5.1 Market Overview
8.5.1.1 Public
8.5.1.2 Private
8.6 Global Acute Respiratory Syndrome Treatment Market by Region
8.6.1 Market Overview
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Middle East and Africa
8.6.1.5 Latin America
9 North America Acute Respiratory Syndrome Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3 Canada
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
10 Europe Acute Respiratory Syndrome Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2017-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 Germany
10.3.1 Historical Trend (2017-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 France
10.4.1 Historical Trend (2017-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Italy
10.5.1 Historical Trend (2017-2023)
10.5.2 Forecast Trend (2024-2032)
10.6 Others
11 Asia Pacific Acute Respiratory Syndrome Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2017-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 Japan
11.3.1 Historical Trend (2017-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 India
11.4.1 Historical Trend (2017-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 ASEAN
11.5.1 Historical Trend (2017-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Australia
11.6.1 Historical Trend (2017-2023)
11.6.2 Forecast Trend (2024-2032)
11.7 Others
12 Latin America Acute Respiratory Syndrome Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2017-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Argentina
12.3.1 Historical Trend (2017-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Mexico
12.4.1 Historical Trend (2017-2023)
12.4.2 Forecast Trend (2024-2032)
12.5 Others
13 Middle East and Africa Acute Respiratory Syndrome Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2017-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 United Arab Emirates
13.3.1 Historical Trend (2017-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 Nigeria
13.4.1 Historical Trend (2017-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 South Africa
13.5.1 Historical Trend (2017-2023)
13.5.2 Forecast Trend (2024-2032)
13.6 Others
14 Global Acute Respiratory Syndrome Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 AIkido Pharma Inc.
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Aceto Corporation
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Global BioLife Inc Ltd
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Faron Pharmaceuticals
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 PhaseBio Pharmaceuticals
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Sage Therapeutics
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Emergent BioSolutions
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Direct Biologics
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Kiniksa Pharmaceuticals, Ltd
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Biomarck Pharmaceuticals, Ltd.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Athersys, Inc.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
16 Global Acute Respiratory Syndrome Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The acute respiratory syndrome treatment market is driven by the rising respiratory issues, especially with the mutating variants of COVID-19 over the historical period.
Based on the drug classification, the market is categorised into vasoconstrictors, bronchodilators, steroids, antibiotics, nitric oxide, surfactants, sedatives and paralytics, among others.
Based on the class, the market is segmented into oral, parenteral, and inhalation, among others.
The treatment channels in this market are public and private.
The different regions in the market are North America, Europe, Asia Pacific, Latin America, the Middle East and Africa.
As fluid accumulates in your lungs' little, elastic air sacs (alveoli), acute respiratory distress syndrome (ARDS) develops. Less oxygen enters your circulation because of the fluid's ability to prevent your lungs from filling with enough air. This deprives your organs of the oxygen they require to function.
The key companies involved in this market are AIkido Pharma Inc., Aceto Corporation, Global, BioLife Inc Ltd, Faron Pharmaceuticals, PhaseBio Pharmaceuticals, Sage Therapeutics, Emergent BioSolutions, Direct Biologics, Kiniksa Pharmaceuticals, Ltd, Biomarck Pharmaceuticals, Ltd., Athersys, Inc. among others.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.